Stock Code: 002940 Stock Abbreviation: AngLiKang
Zhejiang AngLiKang Pharmaceutical CO., LTD.
(No. 1000, North Shengzhou Avenue, Shengzhou City, Zhejiang Province)
2025 Prospectus for Issuance of A-Shares to Specific Targets
(Registration Draft)
Sponsor (Lead Underwriter)
(Orient Securities Building, No. 119, South Zhongshan Road, Huangpu District, Shanghai)
July 2026
Statement
The Company and all directors, members of the audit committee, and senior management warrant that the contents of this prospectus and other information disclosure materials do not contain false records, misleading statements, or major omissions, and assume corresponding legal liability for their authenticity, accuracy, and completeness.
The person in charge of the Company, the person in charge of accounting work, and the person in charge of the accounting institution guarantee the authenticity and completeness of the financial and accounting data in this prospectus.
Any decision or opinion made by the China Securities Regulatory Commission or the Shenzhen Stock Exchange regarding this issuance does not indicate their guarantee of the authenticity, accuracy, or completeness of the application documents and disclosed information, nor does it constitute a substantive judgment or guarantee of the issuer's profitability, investment value, or investor returns. Any statement to the contrary is a false statement.
According to the provisions of the Securities Law, after the securities are issued in accordance with the law, the issuer is responsible for changes in its operations and earnings. Investors shall independently judge the investment value of the issuer, make their own investment decisions, and bear the investment risks caused by changes in the issuer's operations and earnings or fluctuations in securities prices after the issuance.
Important Matters Notice
The Company specifically reminds investors to carefully read the full text of this prospectus and pay special attention to the following important matters and company risks before making investment decisions.
I. Special Risk Warnings
Investors are reminded to carefully read the content of "Section VI: Risk Factors Related to This Issuance" in this prospectus and pay special attention to the following risks:
(I) Drug R&D Risks
The Company's investment project for this fund-raising plans to invest in the research and development of innovative drugs, which are characterized by high investment, high risk, and long cycles. As of the signing date of this prospectus, the ALK-N001 monotherapy indication has entered the Ib or Ib/II clinical trial stage, while the combination therapy plan is in the preclinical research stage, and IND application preparations are underway. According to the clinical trial plan, ALK-N001 monotherapy for various indications is expected to enter Phase II pivotal clinical trials or Phase III clinical trials as early as 2028, and ALK-N001 combination therapy for various indications is expected to enter Phase III clinical trials as early as 2030. There is still a long R&D process before entering Phase III clinical trials and the registration and listing application stage. According to the article "Multi-dimensional Analysis of Phase Success Rates and Approval Possibilities of Chemical Innovative Drug R&D Projects in Chinese Pharmaceutical Enterprises" published by the Yaozhi Data Team in Volume 34, Issue 6 of "China Pharmaceuticals," the success rates for chemical innovative drugs in Phase I, Phase II, Phase III, and registration application stages are 52.1%, 47.2%, 64.2%, and 80.3% respectively. For oncology innovative drugs, the success rates are 41.39%, 37.29%, 75.68%, and 71.43% respectively. Innovative drug products, especially oncology drugs, require a long cycle from preclinical research to clinical trials, and finally to obtaining a drug registration certificate and achieving large-scale industrial production. The success rate of oncology innovative drug products at each stage is lower than that of other innovative drugs, with higher risks and greater uncertainty.